Mutant-to-wild-type allelic ratio, insertion site, ITD length, karyotype, and the presence of a mutation in the NPM1 gene appear to further influence the prognostic utility of FLT3-ITD in patients with newly diagnosed FLT3-ITD-mutated AML. The gene discussed is FLT3; the disease is acute myeloid leukemia.